
RNAi Drug Developer

Biological New Drug Developer

Gene and Cell Therapy Drug Developer

Developer of Innovative Class III Active Implantable Products

Invasive High-Throughput Ultra-Thin Flexible Brain-Computer Interface System Developer
VENTURE50 Investment Value Enterprises, after nineteen years of deep cultivation, have witnessed countless companies leap from "new shoots" to become "unicorns," and have personally experienced China's industrial upgrading from model innovation to cutting-edge technological breakthroughs over the past 20-plus years.
Good News from Apricot Capital's Partner Companies! Argo Biopharma, Evopoint Biosciences, Shanghai Tianze Yuntai Biomedical, and United InnoMed Listed Among the "Top 200", BCIFlex Joins the "Emerging 100", Shining Together on the Industry Rankings!
In 2025, the venture capital market gradually stabilized, with capital assembling in the hard technology sector. Artificial intelligence, hard technology, healthcare, and new energy materials constitute the core industry tracks, while embodied intelligence, advanced manufacturing, synthetic biology, commercial aerospace, and clean energy are becoming the key directions for capital to lay out "future industries." New energy storage technologies such as solid-state batteries, localization of semiconductor equipment production in China, and commercialization of quantum computing are driving the iterative upgrading of the science and technology industry through technological breakthroughs.

Argo
Evopoint Biosciences
Shanghai Tianze Yuntai Biomedical Co., Ltd.
United InnoMed

BCIFlex
About the List
The preliminary evaluation of 2025 VENTURE50 lasted for two months, during which more than a hundred judges from investment institutions comprehensively assessed over 2,600 enterprises based on dimensions such as growth speed, technological barriers, commercialization progress, team characteristics, operational capabilities, and industry alignment. In the end, 300 enterprises advanced to the final evaluation. The "Fengyun 200" focuses on mature technology innovation companies, while the "Xinya 100" targets early-stage potential enterprises, covering hot sectors such as AI, semiconductors, new energy, and healthcare.
